about
An alternative promoter of the human neuronal nitric oxide synthase gene is expressed specifically in Leydig cellsCellular mechanisms of nitric oxide-induced relaxation of corporeal smooth muscle in the guinea-pigSildenafil suppresses the proliferation and enhances the apoptosis of hemangioma endothelial cells.The pathophysiological role of prostaglandins in penile erection.Male fertility following spinal cord injury: an update.NO as a signalling molecule in the nervous system.Exploring scientifically proven herbal aphrodisiacsInvolvement of beta 3-adrenergic receptor activation via cyclic GMP- but not NO-dependent mechanisms in human corpus cavernosum function.Potassium channel subtypes as molecular targets for overactive bladder and other urological disorders.Ultrastructural and morphometrical study of preimplantation endometrium in superovulated mice treated with progesterone or Sildenafil.A Review of the Pathophysiology and Novel Treatments for Erectile Dysfunction.Usefulness of serum fetuin-A level as a marker of erectile dysfunction.A novel aphrodisiac compound from an orchid that activates nitric oxide synthases.Gene transfer of extracellular SOD to the penis reduces O2-* and improves erectile function in aged rats.Effects of insulin-like growth factor-1 on the relaxation responses of the cavernous smooth muscle from aged rats.Intracavernosal administration of sodium nitrite as an erectile pharmacotherapy.Changes in nerve- and endothelium-mediated contractile tone of the corpus cavernosum in a mouse model of pre-mature ageing.Effect of phosphodiesterase-5 inhibitor, sildenafil (Viagra), in animal models of airways disease.Effect of combination endothelial nitric oxide synthase gene therapy and sildenafil on erectile function in diabetic rats.Yohimbine enhances the effect of sildenafil on erectile process in rats.Neuroprotection by sildenafil: neuronal networks potentiation in acute experimental stroke.Psychological determinants of erectile dysfunction among middle-aged men.Relaxant effect of a metal-based drug in human corpora cavernosa and its mechanism of action.
P2860
Q28344824-22EB0BE5-E99D-4A7D-97E8-802ECDB46F4AQ28345089-86F2C692-2B19-48AA-B69C-25230F973A0FQ33744352-B88B8092-8900-4421-967E-97E8ABC6A297Q34241030-3CC4F124-9C17-487E-90A3-9B5E541DDEB7Q34500514-F4E0899E-706D-4D1C-8427-7CBB2C291BF8Q34551365-DAE157DE-7A63-4938-BF6C-A4689B46A6F5Q34655086-226FCF11-EBE3-4E20-ABB7-0947684AB262Q34983511-D67306B2-F475-48C6-8383-08A95B96A02EQ35911129-175FE5C3-C118-4286-8323-74CD17E4C558Q37615339-C266B6E0-D9BC-44C6-9243-51DC9C6057F2Q37820206-DFB00E2C-3AFA-467D-856E-F075FDA4552CQ38829614-2BA71620-7036-43DC-BC30-45236E5A3604Q39496014-62B6A296-1C73-4B5B-8EFE-DABA470A2E96Q40680273-5AF8F082-6FC2-4AEE-BE07-C6FED0AAA7F2Q41099902-97D8BA2E-1F8B-4759-9155-D91080B99508Q42961704-A43E39F2-4828-4ABD-815A-B3E9EB77A006Q44610649-32B2B1F9-B9D1-4C79-93DB-A600AD24E065Q44641924-701A8BFE-72F1-4BC3-ADE5-7F81229C1A5DQ44764454-3EE38C60-AADC-4751-9DAE-AD92B194F93CQ46640327-96FBB5D9-08DA-456D-AD89-6DA2AF7F4B98Q46656592-B8C7067B-2FED-4BF9-A1A5-E910C3914025Q47823245-48F26B25-571D-4285-A6E6-9F698F5B69EFQ53462040-578B21AC-A569-436C-ABE3-3E016B32B6DE
P2860
description
2000 nî lūn-bûn
@nan
2000 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Pharmacotherapy for erectile dysfunction.
@ast
Pharmacotherapy for erectile dysfunction.
@en
Pharmacotherapy for erectile dysfunction.
@nl
type
label
Pharmacotherapy for erectile dysfunction.
@ast
Pharmacotherapy for erectile dysfunction.
@en
Pharmacotherapy for erectile dysfunction.
@nl
prefLabel
Pharmacotherapy for erectile dysfunction.
@ast
Pharmacotherapy for erectile dysfunction.
@en
Pharmacotherapy for erectile dysfunction.
@nl
P2093
P1476
Pharmacotherapy for erectile dysfunction.
@en
P2093
Bivalacqua TJ
Champion HC
Hellstrom WJ
Kadowitz PJ
P304
P356
10.1016/S0165-6147(00)01587-X
P577
2000-12-01T00:00:00Z